Showing 3701-3710 of 4164 results for "".
- Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitishttps://modernod.com/news/krystal-biotech-announces-first-patient-dosed-in-phase-12-trial-of-kb801-for-the-treatment-of-neurotrophic-keratitis/2482883/Krystal Biotech announced that the first patient has been dosed in its phase 1/2 clinical trial (EMERALD-1), a 2:1 randomized, double-masked, multicenter, placebo-controlled study evaluating KB801 for the treatment of neurotrophic keratitis (NK). KB801 is a redosable eye drop gene
- BlueRock Therapeutics Announces First Patient Treated in Phase 1/2a Trial of OpCT-001 for Primary Photoreceptor Diseaseshttps://modernod.com/news/bluerock-therapeutics-announces-first-patient-treated-in-phase-12a-trial-of-opct-001-for-primary-photoreceptor-diseases/2482877/Bayer and BlueRock Therapeutics announced that the first patient received the investigational therapy in CLARICO, a phase 1/2a clinical trial of OpCT-001, an investigational induced pluripotent stem cell (iPSC)-derived cell therapy for the treatment of primary photoreceptor diseases. OpCT-00
- First Patient Dosed in the Phase 1 Trial of PulseSight Therapeutics’ Investigational PST-611 Treatment for Dry AMD/GAhttps://modernod.com/news/first-patient-dosed-in-the-phase-1-trial-of-pulsesight-therapeutics-investigational-pst-611-treatment-for-dry-amdga/2482874/PulseSight Therapeutics has announced that the first patient has been dosed in its phase 1 clinical trial (PST-611-CT1) assessing the safety and tolerability of its lead program, PST-611, in humans. PST-611 is a first-in-class non-viral vectorized
- Ashvattha Therapeutics to Present Phase 2 DME and Wet AMD Datahttps://modernod.com/news/ashvattha-therapeutics-to-present-phase-2-dme-and-wet-amd-data/2482846/Ashvattha Therapeutics announced it will present new data focusing on previously reported phase 2 clinical data on migaldendranib, its investigational subcutaneous therapy for diabetic macular edema (DME) and wet age-related macular degeneration (AMD), which could offer a
- SpliceBio Secures $135M Series B to Advance Gene Therapy for Stargardt Diseasehttps://modernod.com/news/splicebio-secures-135m-series-b-to-advance-gene-therapy-for-stargardt-disease/2482845/SpliceBio announced the closing of a $135 million Series B financing round to support the clinical advancement of SpliceBio’s lead gene therapy candidate, SB-007, for Stargardt disease. There are currently no approved treatments for the disease, which is
- ViGeneron Rebrands as VeonGen Therapeutics; Announces FDA Rare Pediatric Disease Designation for Lead Gene Therapyhttps://modernod.com/news/vigeneron-rebrands-as-veongen-therapeutics-announces-fda-rare-pediatric-disease-designation-for-lead-gene-therapy/2482837/VeonGen Therapeutics announced its rebranding from ViGeneron to reflect its evolution into a clinical-stage genetic medicine company focused on developing transformative gene therapies for patients with high unmet medical needs. VeonGen has advanc
- EyeCool Therapeutics Announces Positive Results from Pilot Study in Patients with Chronic Ocular Surface Pain (COSP)https://modernod.com/news/eyecool-therapeutics-announces-positive-results-from-pilot-study-in-patients-with-chronic-ocular-surface-pain-cosp/2482799/EyeCool Therapeutics announced positive clinical data from a double-masked, randomized controlled pilot study of 31 patients in Australia evaluating the safety and efficacy of its investigational device (ETX-4143) for the treatment of Chronic Ocular Surface Pain (COSP). T
- Topcon Healthcare Launches IDHea to Fuel AI and Digital Health Innovation from the Eyehttps://modernod.com/news/topcon-healthcare-launches-idhea-to-fuel-ai-and-digital-health-innovation-from-the-eye/2482792/Topcon Healthcare announced the launch of the Institute of Digital Health (IDHea), an ocular data-as-a-service platform designed to accelerate AI research and digital health innovation. IDHea is designed to provide fast and secure access to unique real-world and clinical trial datasets,
- Chengdu Origen and Vanotech Announce First Patient Dosed in Phase 1 Trial of Gene Therapy for Wet AMDhttps://modernod.com/news/chengdu-origen-and-vanotech-announce-first-patient-dosed-in-phase-1-trial-of-gene-therapy-for-wet-amd/2482781/Chengdu Origen Biotechnology and Vanotech announced that the first patient dosed in the VAN-2401 multicenter phase 1 clinical trial evaluating treatment with KH658 for patients with wet age-related macular degeneration (AMD). This multicenter, open-lab
- Topcon Healthcare Appoints Daniela Ferrara, MD, PhD, as Chief Medical Officerhttps://modernod.com/news/topcon-healthcare-appoints-daniela-ferrara-md-phd-as-chief-medical-officer/2482764/Topcon Healthcare announced the appointment of Daniela Ferrara, MD, PhD, as its new Chief Medical Officer (CMO). In her new role, Dr. Ferrara will lead Topcon Healthcare’s global medical strategy, overseeing clinical r